Article
Outbreak of Mycobacterium chelonae in France
26 Oct 2010
Abstract excerpt
Background Since the beginning of 2014, an increasing number of second-generation direct-acting antiviral agents (DAAs) have been approved in Italy for treating chronic hepatitis C virus (HCV) improving patients’ perspectives and increasing treatment outcomes. In order to achieve high-quality treatment with these costly drugs, DAA-2 prescriptions are subject to strict rules (specific drug for specific patient...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
